Eficacia y seguridad de la terapia con inhibidores de la PCSK9 en el tratamiento de las dislipidemias y riesgo cardiovascular
Dyslipidemia, defined as an alteration in blood lipid levels. In particular, cholesterol and triglycerides are a key risk factor for cardiovascular health. Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are mechanisms used to treat diseases related to excess cholesterol in the blood....
Guardat en:
| Autor principal: | |
|---|---|
| Format: | bachelorThesis |
| Idioma: | spa |
| Publicat: |
2025
|
| Matèries: | |
| Accés en línia: | https://dspace.uniandes.edu.ec/handle/123456789/19185 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Afegir etiqueta | Sumari: | Dyslipidemia, defined as an alteration in blood lipid levels. In particular, cholesterol and triglycerides are a key risk factor for cardiovascular health. Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are mechanisms used to treat diseases related to excess cholesterol in the blood. Objective: To establish the efficacy and safety of PCSK9 inhibitors in the treatment of dyslipidemia and their impact on cardiovascular risk. Methodology: A qualitative methodology with a cross-sectional situational diagnostic design was used. The study was based on documentary review and analysis of scientific literature to identify innovative and safe therapies. Review sheets and documentary guides were used to organize and systematize the information collected. Results: PCSK9 inhibitors, such as evolocumab and alirocumab, showed to be effective for LDL cholesterol reduction in patients with dyslipidemia resistant to conventional treatments, although access to them remains limited due to their high costs and restriction in public health systems. Conclusions: PCSK 9 inhibitors represent a promising alternative in the management of high-risk dyslipidemia by effectively reducing LDL cholesterol and cardiovascular events in high-risk patients. |
|---|